FY2029 EPS Estimates for Pyxis Oncology Raised by Analyst

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at HC Wainwright lifted their FY2029 earnings estimates for shares of Pyxis Oncology in a note issued to investors on Tuesday, March 24th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.27 for the year, up from their previous forecast of $0.21. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The business had revenue of $11.04 million during the quarter.

A number of other research analysts also recently weighed in on the company. Wall Street Zen downgraded Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Royal Bank Of Canada lowered their price target on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. Finally, Stifel Nicolaus dropped their price objective on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Pyxis Oncology Price Performance

Shares of NASDAQ:PYXS opened at $1.36 on Wednesday. The company’s 50-day moving average price is $1.52 and its two-hundred day moving average price is $2.51. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.55. The stock has a market capitalization of $84.67 million, a PE ratio of -1.05 and a beta of 1.45.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PYXS. Maia Wealth LLC acquired a new stake in Pyxis Oncology during the fourth quarter worth approximately $25,000. Engineers Gate Manager LP acquired a new position in shares of Pyxis Oncology in the fourth quarter valued at approximately $26,000. Fox Run Management L.L.C. bought a new position in shares of Pyxis Oncology during the fourth quarter worth approximately $26,000. Avanza Fonder AB acquired a new stake in Pyxis Oncology during the 4th quarter worth approximately $31,000. Finally, XTX Topco Ltd acquired a new stake in Pyxis Oncology during the 2nd quarter worth approximately $40,000. 39.09% of the stock is owned by institutional investors.

More Pyxis Oncology News

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: Quarterly results beat expectations — PYXS reported a loss per share of ($0.29) vs. consensus ($0.35) and generated $11.04M of revenue, showing better-than-expected near-term performance. This beats helped validate recent operations and may support longer-term valuation recovery. Earnings Press Release
• Positive Sentiment: Clinical progress — Pyxis completed target enrollment in the Phase 1 monotherapy dose‑expansion of MICVO (micvotabart pelidotin) in 2L+ R/M HNSCC in Q1 2026. Completion of enrollment advances a near‑term clinical catalyst (data/readout) that could materially move the stock if results are positive. Business Update
• Positive Sentiment: Analyst support remains — HC Wainwright reaffirmed a “buy” rating with a $7 price target, signaling ongoing institutional conviction in the story despite the low share price. HC Wainwright Note
• Neutral Sentiment: Short-interest reporting appears anomalous — multiple March filings list 0 shares short and 0.0 days-to-cover (with NaN changes), suggesting a likely data/reporting issue rather than a meaningful shift in short positioning. Treat this as unreliable until corrected by official exchanges.
• Negative Sentiment: Price target cut by a covering analyst — Stifel Nicolaus lowered its target from $9.00 to $8.00 (but kept a “buy” rating). A lower target, even with a buy rating, can pressure sentiment and weigh on the stock in the near term. Stifel Note

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.